ArticleScientific reports2023
Mapping brucellosis risk in Kenya and its implications for control strategies in sub-Saharan Africa.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- High brucellosis prevalence and risk among children aged 5-14 years in Kenyan pastoral health facilities: A facility-based surveillance study.PLoS neglected tropical diseases · 2026Article
- Knowledge, Attitudes, Practices, and Information Pathways Related to Brucellosis Among Adults in Najran City, Saudi Arabia: A Stratified Time-Location Cross-Sectional Study.Tropical medicine and infectious disease · 2026Article
- Seroincidence of Brucella spp. infection among humans and livestock in a pastoralist setting in Northern Kenya.Scientific reports · 2026Article
- Laboratory Surveillance of Bovine Brucellosis: Predictors of Rose Bengal Test Positivity in Mpumalanga Province, South Africa (2021-2024).Veterinary sciences · 2026Article
- Insight into the genetic diversity ofMicrobiology spectrum · 2026Article
- High prevalence of Q fever among patients clinically diagnosed with brucellosis in a Kenyan pastoralist community.Frontiers in epidemiology · 2026Article
- Bovine brucellosis seropositivity in Mpumalanga Province, South Africa, 2021-2024: Temporal, and spatial trends.PloS one · 2026Article
- Design of a Prospective Human-Animal Cohort Study to Evaluate the Role of Camels and Other Livestock Species in the Transmission ofInternational journal of environmental research and public health · 2025Article
- Integrated Surveillance for Human and Animal Brucellosis in Kenya: A Predictive Analysis.Tropical medicine and infectious disease · 2025Article
- National serosurvey and risk mapping reveal widespread distribution of Coxiella burnetii in Kenya.Scientific reports · 2025Article
- Social network analysis of key stakeholders in Brucellosis prevention in Western Iran.Tropical medicine and health · 2025Article
- Article
- Review of the Current Status on Ruminant Abortigenic Pathogen Surveillance in Africa and Asia.Veterinary sciences · 2024Review
- Seroprevalence ofFrontiers in veterinary science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 4 countries.
Funding
Abstract
In Sub-Saharan Africa (SSA), effective brucellosis control is limited, in part, by the lack of long-term commitments by governments to control the disease and the absence of reliable national human and livestock population-based data to inform policies. Therefore, we conducted a study to establish the national prevalence and develop a risk map for Brucella spp. in cattle to contribute to plans to eliminate the disease in Kenya by the year 2040. We randomly generated 268 geolocations and distributed them across Kenya, proportionate to the area of each of the five agroecological zones and the associated cattle population. Cattle herds closest to each selected geolocation were identified for sampling. Up to 25 cattle were sampled per geolocation and a semi-structured questionnaire was administered to their owners. We tested 6,593 cattle samples for Brucella immunoglobulin G (IgG) antibodies using an Enzyme-linked immunosorbent assay (ELISA). We assessed potential risk factors and performed spatial analyses and prevalence mapping using approximate Bayesian inference implemented via the integrated nested Laplace approximation (INLA) method. The national Brucella spp. prevalence was 6.8% (95% CI: 6.2-7.4%). Exposure levels varied significantly between agro-ecological zones, with a high of 8.5% in the very arid zone with the lowest agricultural potential relative to a low of 0.0% in the agro-alpine zone with the highest agricultural potential. Additionally, seroprevalence increased with herd size, and the odds of seropositivity were significantly higher for females and adult animals than for males or calves. Similarly, animals with a history of abortion, or with multiple reproductive syndromes had higher seropositivity than those without. At the herd level, the risk of Brucella spp. transmission was higher in larger herds, and herds with a history of reproductive problems such as abortion, giving birth to weak calves, or having swollen testes. Geographic localities with high Brucella seroprevalence occurred in northern, eastern, and southern regions of Kenya all primarily characterized by semi-arid or arid agro-ecological zones dominated by livestock pastoralism interspersed with vast areas with mixed livestock-wildlife systems. The large spatial extent of our survey provides compelling evidence for the widespread geographical distribution of brucellosis risk across Kenya in a manner easily understandable for policymakers. Our findings can provide a basis for risk-stratified pilot studies aiming to investigate the cost-effectiveness and efficacy of singular and combined preventive intervention strategies that seek to inform Kenya's Brucellosis Control Policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.